GNLX Valuation Metrics
FCF$-26.37M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Genelux Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Genelux Corp
Did you know?
Capital expenditures increased by 188% from FY24 to FY25.
Current Price
$2.85
+4.01%Profile
Valuation (TTM)
Market Cap$108.45M
P/E-3.37
EV—
P/B9.39
Shares Out38.05M
P/Sales—
Revenue$0.00
EV/EBITDA—
Genelux Corp (GNLX) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →GNLX Valuation & Fair Value Analysis
Genelux Corp (GNLX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is -3.37. Price-to-book ratio is 9.39. PEG ratio is 0.44.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Genelux Corp's intrinsic value.